GT Medical Technologies’ implant delivers radiation therapy directly to the bed of an excised brain tumor—a potential game-changer for people with highly proliferative, hard-to-treat tumors such as glioblastomas. Its GammaTile Therapy is now in use at 75 US hospitals and the firm has raised $26 million over the past three years—not bad for a company that launched its flagship product at the height of the pandemic.
Enrolling Newly Diagnosed Patients with Glioblastoma in the GESTALT Clinical Trial
Kettering Health is now the first provider in the Dayton area to offer GammaTile Therapy.
GT has a number of advantages. Unlike with traditional brachytherapy, the collagen tile provides a buffer around the radiation sources, allowing delivery of the optimal radiation dose while preserving healthy tissue.